Search PubMed⌕ Search

Biomedical subjects

M Akhtar

Publications and source records attributed to M Akhtar.

At least 505 records · Page 28Linked to original sources
PubMed1972

A novel olefinic rearrangement. The enzymic conversion of cholesta-7,9-dien-3 -ol into cholesta-8,14-dien-3 -ol.

1. [3alpha-(3)H]Cholesta-7,9-dien-3beta-ol is converted in high yield into cholesterol by a 10000g(av.) supernatant fraction of rat liver homogenate. 2. Incubation of cholesta-7,9-dien-3beta-ol with [4-(3)H]NADPH and rat liver microsomal fractions under anaerobic conditions resulted in (3)H being incorporated into the 14alpha-position of cholest-7-en-3beta-ol. 3. Under anaerobic conditions in the absence of NADPH cholesta-7,9-dien-3beta-ol was isomerized into cholesta-8,14-dien-3beta-ol by rat liver microsomal fractions.

Anaerobiosis↗
PubMed1971

The formation and reduction of the 14,15-double bond in cholesterol biosynthesis.

It was shown that 100mug quantities of 4,4'-dimethyl[2-(3)H(2)]cholesta-8,14-dien-3beta-ol (IIIa), tritiated cholesta-8,14-dien-3beta-ol, 4,4'-dimethyl[2-(3)H(2)]cholesta-7,14-dien-3beta-ol, dihydro[2-(3)H(2)]lanosterol and [24-(3)H]lanosterol were converted by a 10000g supernatant of rat liver homogenate into cholesterol in 17%, 54%, 6%, 9.5% and 24% yields respectively. From an incubation of dihydro[3alpha-(3)H]lanosterol with a rat liver homogenate in the presence of a trap up to 38% of the radioactivity was found to be associated with a fraction that was unambiguously shown to be 4,4'-dimethylcholesta-8,14-dien-3beta-ol. Another related compound, 4,4'-dimethylcholesta-7,14-dien-3beta-ol was also shown to be equally effective in its ability to trap compound (IIIa) from an incubation of dihydro[3alpha-(3)H]lanosterol. The mechanism of the further conversion of the compound (IIIa) into cholesterol occurred by the reduction of the 14,15-double bond and involved the addition of a hydrogen atom from the medium to C-15 and another from the 4-position of NADPH to C-14. Two possible mechanisms for the removal of the 14alpha-methyl group in sterol biosynthesis are discussed.

Animals↗
PubMed1971

Chemical composition of an oestrogen-induced calcium-binding glycolipophosphoprotein in Xenopus laevis.

1. Oestrogen treatment has previously been shown to induce the formation of large amounts of a serum protein, vitellogenin (xenoprotein), in Xenopus laevis. Vitellogenin was purified from serum by dimethylformamide precipitation and was shown to be homogeneous by a variety of electrophoretic techniques. 2. The molecular weight of vitellogenin was estimated by gel filtration to be about 6x10(5). The chemical constituents of vitellogenin were determined and lead to the characterization of this protein as a serum calcium-binding glycolipophosphoprotein. 3. The extractable lipid accounted for 12% of vitellogenin. Gas-liquid-chromatographic analysis of the saponified lipid moiety showed the presence of palmitic acid, palmitoleic acid, stearic acid, oleic acid and linoleic acid in the molecular proportions 6.8: 1.5: 1.0: 3.6: 1.4. 4. The carbohydrate moiety consisted of 0.4g of hexose, 0.77g of hexosamine and 0.18g of sialic acid/100g of vitellogenin. 5. The calcium and phosphorus contents were 0.85 and 1.65g/100g of vitellogenin respectively. 6. Serum from oestrogen-treated animals injected with (45)CaCl(2) contained 9.7 times the radioactivity present in serum from untreated (45)CaCl(2)-injected animals. Of the radioactivity due to (45)CaCl(2) in the serum of oestrogen-treated animals 72% was non-diffusible on dialysis. Of this activity 65.4% was associated with the vitellogenin band on cellulose acetate electrophoresis.

Animals↗
PubMed1971

Studies on the induction and biosynthesis of vitellogenin, an oestrogen-induced glycolipophosphoprotein.

1. Oestrogen treatment induces the formation of a Ca(2+)-binding glycolipophosphoprotein, vitellogenin, in Xenopus laevis. 2. The incorporation of l-[4,5-(3)H]-leucine into vitellogenin in vivo and in vitro was observed 12-24h after hormone treatment and increased progressively up to 21 days after treatment. 3. Vitellogenin is shown to be the major protein component biosynthesized and released into the incubation medium in vitro by livers from oestrogen-treated animals. 4. The biosynthesis in vitro of vitellogenin was inhibited by cycloheximide and carbonyl cyanide m-chlorophenylhydrazone, stimulated by increased Ca(2+) concentrations and decreased by raising the incubation temperature from 22 to 37 degrees C. 5. Incorporation of labelled amino acids into vitellogenin began after approx. 2h. No lag phase was noted for the incorporation of labelled amino acids into total tissue proteins. 6. The incorporation of label from [(32)P]phosphate and [2-(14)C]acetate into the protein as well as into the lipid moiety of vitellogenin showed a lag phase similar to that noted for the incorporation of amino acids. 7. These results suggest that the release of vitellogenin into the incubation medium occurs about 2h after the initiation of its biosynthesis.

Acetates↗